MAPK8 and cancer: Among them, mitogen-activated protein kinases (MAPKs), including c-Jun N-terminal kinase (JNK), extracellular signal-regulated kinase (ERK), and p38 MAPK, are altered in several types of cancer, and pharmacologically selective inhibition of MAPKs has become a candidate target for tumor treatment [20, 21].